Cis-targeting anti-PD1/cytokine - OSE Immunotherapeutics
Latest Information Update: 08 Jun 2024
At a glance
- Originator Boehringer Ingelheim
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours